Información:
Error:
ID
31752
Descripción
A Study of Noscapine HCl (CB3304 ) in Patients With Relapsed or Refractory Multiple Myeloma; ODM derived from: https://clinicaltrials.gov/show/NCT00912899
Link
https://clinicaltrials.gov/show/NCT00912899
Palabras clave
Versiones (1)
- 25/9/18 25/9/18 -
Titular de derechos de autor
See clinicaltrials.gov
Subido en
25 de septiembre de 2018
DOI
Para solicitar uno, por favor iniciar sesión.
Licencia
Creative Commons BY 4.0
Comentarios del modelo :
Puede comentar sobre el modelo de datos aquí. A través de las burbujas de diálogo en los grupos de elementos y elementos, puede agregar comentarios específicos.
Comentarios de grupo de elementos para :
Comentarios del elemento para :
Para descargar modelos de datos, debe haber iniciado sesión. Por favor iniciar sesión o Registrate gratis.
Eligibility Refractory Multiple Myeloma NCT00912899
Eligibility Refractory Multiple Myeloma NCT00912899
- StudyEvent: Eligibility
Similar models
Eligibility Refractory Multiple Myeloma NCT00912899
- StudyEvent: Eligibility
Name
Tipo
Description | Question | Decode (Coded Value)
Tipo de datos
Alias
Multiple Myeloma Advanced
Item
advanced multiple myeloma.
boolean
C0026764 (UMLS CUI [1,1])
C0205179 (UMLS CUI [1,2])
C0205179 (UMLS CUI [1,2])
Disease Progression | Status post Prior Therapy Course Quantity | Steroids Quantity | Biological Response Modifiers Quantity | Alkylating Agents Quantity | bortezomib | Velcade
Item
progression after ≥ 2 lines of prior therapy, including at least one steroid, one immunomodulatory agent (imid), one alkylator, and bortezomib (velcade®).
boolean
C0242656 (UMLS CUI [1])
C0231290 (UMLS CUI [2,1])
C1514463 (UMLS CUI [2,2])
C0750729 (UMLS CUI [2,3])
C1265611 (UMLS CUI [2,4])
C0038317 (UMLS CUI [3,1])
C1265611 (UMLS CUI [3,2])
C0005525 (UMLS CUI [4,1])
C1265611 (UMLS CUI [4,2])
C0002073 (UMLS CUI [5,1])
C1265611 (UMLS CUI [5,2])
C1176309 (UMLS CUI [6])
C1174739 (UMLS CUI [7])
C0231290 (UMLS CUI [2,1])
C1514463 (UMLS CUI [2,2])
C0750729 (UMLS CUI [2,3])
C1265611 (UMLS CUI [2,4])
C0038317 (UMLS CUI [3,1])
C1265611 (UMLS CUI [3,2])
C0005525 (UMLS CUI [4,1])
C1265611 (UMLS CUI [4,2])
C0002073 (UMLS CUI [5,1])
C1265611 (UMLS CUI [5,2])
C1176309 (UMLS CUI [6])
C1174739 (UMLS CUI [7])
ECOG performance status
Item
ecog performance status of either 0 or 1.
boolean
C1520224 (UMLS CUI [1])
Prior Chemotherapy | Antimitotic Agents
Item
prior chemotherapy with antimicrotubule agents
boolean
C1514457 (UMLS CUI [1])
C0003379 (UMLS CUI [2])
C0003379 (UMLS CUI [2])
Metastatic malignant neoplasm to brain | Secondary malignant neoplasm of spinal cord
Item
metastasis involving the brain or spinal cord
boolean
C0220650 (UMLS CUI [1])
C0347016 (UMLS CUI [2])
C0347016 (UMLS CUI [2])
Lung disease | Heart Disease
Item
clinically significant lung or heart disease
boolean
C0024115 (UMLS CUI [1])
C0018799 (UMLS CUI [2])
C0018799 (UMLS CUI [2])
Electrocardiogram abnormal
Item
abnormal electrocardiogram
boolean
C0522055 (UMLS CUI [1])
Eligibility Criteria Additional
Item
please note that there are additional inclusion and exclusion criteria. the study center will determine if you meet all of the criteria.
boolean
C1516637 (UMLS CUI [1,1])
C1524062 (UMLS CUI [1,2])
C1524062 (UMLS CUI [1,2])
Study Subject Participation Status | Counseling Research Personnel
Item
site personnel will explain the trial in detail and answer any question you may have if you do qualify for the study. you can then decide whether or not you wish to participate. if you do not qualify for the trial, site personnel will explain the reasons.
boolean
C2348568 (UMLS CUI [1])
C0010210 (UMLS CUI [2,1])
C0035173 (UMLS CUI [2,2])
C0010210 (UMLS CUI [2,1])
C0035173 (UMLS CUI [2,2])